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ABSTRACT Bullous pemphigoid is an acquired autoimmune subepidermal blister-
ing disease which is associated with mucocutaneous lesions. The type and amount 
of autoantibody deposition may have a role in mucosal lesions. We studied the as-
sociation between mucosal involvement and direct immunofluorescence pattern 
in cutaneous lesions of patients with bullous pemphigoid.
In this retrospective analytical cross-sectional study, we studied the demographic 
data, clinical presentations, and immunopathological findings of 69 patients with 
bullous pemphigoid admitted to our hospital 2008-2016. Patients were allocated 
into two groups on the basis of the mucosal involvement, and direct immunofluo-
rescence patterns were evaluated. The data were analyzed using SPSS version18.
The mean age of patients was 70.9±14.97 (mean ± Standard Deviation) years old. 
In our study, 56.5% of patients were women. All patients showed deposition of 
IgG and C3 in the dermoepidermal junction, with different severity. Patients with 
mucosal involvement (40.6% of cases) had a more prominent deposition of IgG, 
IgA, and C3 at the dermoepidermal junction compared with patients without mu-
cosal involvement, which represented a statistically significant difference (P<0.05). 
Logistic regression analysis showed that lower age, IgA, and C3 deposition (P<0.05) 
were associated with mucosal involvement.
Deposition of IgA and C3 (in addition to IgG) at the dermoepidermal junction seems 
to be a marker of mucosal involvement in patients with bullous pemphigoid. At-
tention to direct immunofluorescence pattern in patients with bullous pemphi-
goid may be helpful in prediction of mucosal involvement in these patients.
KEY WORDS: bullous pemphigoid, direct immunofluorescence, mucosal involve-
ment
INTRODUCTION
Bullous pemphigoid (BP) is an acquired autoim-
mune subepidermal bullous disease. Prevalence of BP 
has been increased in recent years. It usually occurs at 
old ages and is associated with autoantibody produc-
tion, especially IgG antibodies, against hemidesmo-
somal components (BP antigen) (1,2). Other immuno-
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Table 1. Characteristics of basement membrane depositions in patients with bullous pemphigoid 
with and without mucosal involvement
Basement membrane 
depositions
Patients without mucosal 
involvement
Number (%)







1+ 19 (46.34) 6 (21.43) 25 (36.23)
0.0292+ 17 (41.46) 12 (42.86) 29 (42.03)
3+ 5 (12.20) 10 (35.71) 15 (21.74)
C3
1+ 15 (36.59) 3 (10.71) 18 (26.09)
0.0342+ 16 (39.02) 12 (42.86) 28 (40.58)
3+ 10 (24.39) 13 (46.43) 23 (33.33)
IgM
0 28 (68.29) 17 (60.71) 45 (65.22)
0.516
1+ or 2+ 13 (31.71) 11 (39.29) 24 (34.78)
IgA
0 28 (68.29) 10 (35.71) 38 (55.07)
0.008
1+ or 2+ 13 (31.71) 18 (64.29) 31 (44.93)
*P-values were calculated using Chi-Square test
reactant depositions include IgM, IgA autoantibod-
ies, and complement component 3 (C3). Cutaneous 
lesions usually present as urticarial papules, plaques, 
and inflammatory or non-inflammatory intact bullae 
(1). About one third of patients with BP have mucosal 
involvement (2). Some authors believe that the type 
and amount of autoantibody depositions, especially 
IgA antibodies, may have a role in mucosal lesions in 
these patients, but there are contradictory reports in 
this regard (3,4). We studied the association between 
mucosal involvement and direct immunofluores-
cence (DIF) pattern of cutaneous lesions in patients 
with BP. Our hypothesis was that mucosal erosions 
are correlated with a different variety of antibody de-
positions.
PATIENTS AND METHODS
This research project was a retrospective analyti-
cal cross-sectional study; we evaluated the demo-
graphic data (age and sex), smoking history, clinical 
presentations (localized or generalized cutaneous 
involvement), histopathological pattern (eosinophil-
rich or not), and immunofluorescence pattern (type 
and amount of immunoreactant depositions) of 69 
patients with BP admitted to Razi hospital, Guilan Uni-
versity of Medical Sciences over the past nine years 
(2008-2016). We reviewed their files in the archive of 
our hospital. All patients with a definite diagnosis of 
BP were allocated into two groups on the basis of oral 
mucosal involvement, after which the DIF patterns of 
their cutaneous lesions were evaluated. Severity of 
basement membrane deposits was evaluated with 
objective assessment of the pathologist, scored from 
1+ (weakest) to 4+ (strongest). Our patients had no 
treatment with immunosuppressive agents prior to 
diagnosis.
No patient had mucosal biopsy and indirect im-
munofluorescence (IIF) study. Diagnosis of BP was 
established on the basis of clinical examination and 
DIF study of the skin lesions. The obligatory criterion 
for diagnosis was linear deposition of IgG and C3 
along the basement membrane on DIF study. Major 
criteria included: 1) Tense blisters and/or erosions 
on the skin and rarely mucosa; 2) Histopathological 
findings of subepidermal blisters associated with eo-
sinophil infiltration (1). Minor criteria were not used 
for diagnosis in this study because immunoblotting, 
enzyme-linked immunosorbent assay (ELISA), and IIF 
techniques were not available in our hospital, so the 
definite diagnosis of BP in our study was based on the 
obligatory criterion plus two major criteria. We used 
SPSS 18 software to analyze the data. The quantitative 
data from this study were examined and presented 
as mean and standard deviation (SD). The qualitative 
data from this study were described by frequency and 
percentage. The relationships between different vari-
ables and mucosal involvement were analyzed using 
the Chi-square test, Mann-Whitney test, and logistic 
regression. A logistic regression model was used to 
assess the associations between effective factors and 
mucosal involvement. In the process of model build-
ing, variables with a P-value <0.2 in the univariate 
analysis were first entered into the multiple regres-
sion model. The association between each variable 
and mucosal involvement in the multiple regression 
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model was expressed as an odds ratio (OR) with 95% 
confidence intervals (CIs). All P-values were two sided; 
significance level was set at P<0.05.
This research project was approved by the Ethics 
committee of Guilan University of Medical Sciences 
(Code: IR.GUMS.REC.1395.206).
RESULTS
Sixty nine patients with BP were enrolled in this 
study. The mean age of patients was 70.9±14.97 years 
old with a variation range of 24-95 years. Most of the 
patients were aged between 70 to 90 years. Two out 
of 69 patients were less than 40 years old: one was 24 
years old and had severe congenital skeletal abnor-
mality, and another was 38 years old. 
More than half of patients (56.5% of cases) were 
women, and 43.5% of cases were men. More than 
one third of patients (40.6% of cases) had mucosal in-
volvement, and there was no significant association 
between mucosal involvement and sex (P=0.683). 
Mean age in the group with mucosal involvement 
was 66.85 years, versus 73.66 years in the group with-
out mucosal involvement (P=0.052).
Characteristics of basement membrane deposi-
tions in patients with BP with and without mucosal 
involvement are presented in Table 1. All patients 
showed depositions of IgG and C3 in the dermoepi-
dermal junction, with different severity on DIF stud-
ies. There was no IgM deposition in 65.2% of patients, 
but 33.3% of cases had 1+ and 1.4% of cases had 2+ 
IgM deposition. In more than half of patients, no IgA 
deposition was detected (55.1% of cases), while 1+ 
IgA deposition and 2+ IgA deposition were found in 
in 40.6% and 4.3% of cases, respectively.  
There was no significant association between IgM 
deposition and mucosal involvement in patients with 
BP (P=0.516), but there was a significant difference in 
IgG, IgA, and C3 depositions at the dermoepidermal 
junction between the two groups (P=0.029, P=0.008, 
and P=0.034, respectively). 
Other information obtained from our data was 
as follows: 87% of cases were non-smokers, 24.6% of 
cases had localized lesions on acral areas, and 5.8% 
of tissue samples were not eosinophil-rich. We did 
not find any significant association between mu-
cosal involvement and smoking history, extent of 
the skin lesions (localized or generalized type), and 
pathologic patterns (eosinophil-rich or not). Mucosal 
involvement in our patients was mainly detected on 
oral examination where intact or hemorrhagic bullae, 
erosion, and desquamation were seen on the hard 
palate and buccal and gingival mucosa. Only four pa-
tients had mucosal involvement on genital and nasal 
areas in addition to oral lesions. The most common 
locations of mucosal involvement were the hard pal-
ate and buccal area, which were involved in 100% 
and 71.4% of cases with mucosal lesions, respectively. 
Tzanck smear evaluation of mucosal lesions was also 
performed for some patients and was negative for 
Tzanck cells.
According to multiple logistic regression analysis, 
the adjusted OR for mucosal involvement associated 
with age was 0.95 (95% CI, 0.91 to 0.99), which indi-
cates that chance of mucosal involvement decreased 
about 5% per each one-year increase in age. IgA de-
position increased the OR of mucosal involvement by 
4.56 (95% CI, 1.31 to 15.96) compared with cases with-
out IgA deposition. Patients with 2+ C3 deposition 
were 5.68 times more likely to have mucosal involve-
ment compared with patients with 1+ C3 deposition 
(95% CI, 1.00 to 32.19). Furthermore, chance of mu-
cosal involvement in 3+ C3 deposition subjects was 
higher than in cases with 1+ C3 deposition (OR=8.40, 
95% CI, 1.31 to 53.84) (Table 2).  
DISCUSSION
BP has been described as a common type of pru-
ritic immunobullous disease which is more preva-
lent in the elderly (2). Mean age of patients in our 
study was lower than reported by Kirtschig et al. and 
more than in studies by Laskaris, Banihashemi, and 
Esmaili et al. (5-7). We performed a search on BP in 
young patients because we found two patients aged 
less than 40. Banihashemi et al. and Esmaili et al. 
Table 2. The final model of the adjusted ORs for 
effective factors on the mucosal involvement 
using logistic regression
variable OR 95% CI P-value
age 0.95 0.91, 0.99 0.013
IgA
no 1.00
yes (1+ or 2+) 4.56 1.31, 15.96 0.017
IgG
+1 1.00
+2 1.16 0.29, 4.62 0.830
+3 2.91 0.45, 18.73 0.261
C3
+1 1.00
+2 5.68 1.00, 32.19 0.050
+3 8.40 1.31, 53.84 0.025
OR: Odds Ratio; CI: Confidence Interval
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described age ranges of 19-115 years and 12-100 
years in their reports (2,7). The exact cause of increase 
in BP incidence after the sixth decade of life is un-
known. Drug intake such as diuretics, analgesics, an-
tibiotics, anti-hypertensives, and neuroleptic agents 
has been incriminated as a triggering factor in induc-
ing BP. Taking such drugs usually increases in old age, 
but genetic predisposition is also of great importance 
(1). Chronic exposure to ultraviolet radiation and un-
derlying skin diseases could expose basement mem-
brane autoantigens to the immune system, which 
results in autoimmune bullous diseases in elderly 
patients (8). On the other hand, neurologic disorders 
have been significantly associated with BP in the el-
derly. The probable etiology for this association could 
be presentation of the neuronal form of BP antigen 
230 in the central nervous system (1).
Prior studies have provided contradicting reports 
on sex predominance in BP, with some reporting fe-
male predominance and some reporting male (1,2,7). 
Our study found more frequent involvement in 
women.
Mucosal involvement was detected in more than 
one third of patients in our study, especially on the 
palate and buccal mucosa, but it has been reported 
with different rates in other studies. Mucosal ero-
sions have been found in 10% to 45% of patients with 
BP, usually occurring on the palate, buccal mucosa, 
tongue, gingiva, and lips, but other mucosal surfaces 
including genital, nasal, anal, or rarely conjunctival 
mucosae may be involved (7-12). Interestingly, Las-
karis et al. reported subclinical mucosal involvement 
in the form of antibody depositions on the basement 
membrane in 80% of patients with BP (6).
In our study, all patients showed IgG and C3 depo-
sitions and some had IgM and IgA depositions on the 
basement membrane in cutaneous lesions; unfortu-
nately we had no mucosal biopsy available.
BP antigens are easily diagnosed and targeted by 
different autoantibodies and complements including 
IgG, IgM, IgA, IgE, and C3 (8). About one third of our 
cases had IgM deposition, and 44.9% of cases had IgA 
deposition, which is more than prior studies that re-
ported 20% and 28% of patients with BP had IgA or 
IgM autoantibodies, respectively (3,13). Christophori-
dis et al. explained that in severe forms of BP, includ-
ing patients with oral involvement, the IIF method 
was indicative of both IgG and IgA production in the 
serum of patients (4); unfortunately, the IIF method 
was not performed in our patients.
Maurice et al. found that half of patients with BP 
with IgA autoantibody had mucosal involvement and 
these cases had more severe disease with delayed 
remission and more recurrences (13). In our study, 
about two third of patients with mucosal involvement 
had IgA deposition, while about one third of cases 
without mucosal involvement had IgA deposition.
Our study showed that IgA production raises the 
chance of mucosal involvement 4.5 times. Also sever-
ity of C3 deposition had a role in mucosal erosions. 
However, the pathogenic role of IgA in development 
of mucosal lesions has not been established, and 
there are contradictory reports in this regard (4,5,14). 
It has been shown in animal models that IgA deposi-
tion may be a trigger for neutrophil chemotaxis, which 
results in basement membrane destruction and mu-
cosal erosions in patients with BP (14); so adjuvants 
with anti-inflammatory effects may be needed in 
these cases. Generally, it seems the presence of sec-
ondary antibodies in addition to IgG is indicative of 
disease severity, and the remission rate in these cases 
has also been low while the recurrence rate during 
the maintenance phase has been high (12,16). Zhou 
et al. reported that there was a correlation between 
mucosal involvement and disease severity (17). Iwata 
et al. showed that there was a correlation between 
the level of IgE antibodies against BP antigen 2 and 
severity of activity of the disease (18). IgE detection 
was not performed for our cases.
A new data-point not present in other studies was 
the lower incidence of mucosal lesions at older ages, 
as a one-year increase in age decreased the chance 
of mucosal involvement by about 5%. This finding 
should be reevaluated in other studies with larger 
sample size. We think that BP antigen presentation in 
mucosal membranes may be decreased in the elderly, 
which should be investigated in future.
We did not have a meticulous scoring system for 
evaluation of disease severity in our patients, but there 
was no significant difference in mucosal involvement 
between localized and generalized disease. Unfor-
tunately, we missed some patients with localized BP 
because such cases were not referred to our hospital; 
consequently, this result was not reliable.
We did not find any correlation between smoking 
and mucosal involvement, which could be explained 
by low frequency of smoking in our study. It has been 
shown that smoking has a protective effect against 
mucosal erosions in patients with pemphigus vul-
garis (19).
Linear IgA/IgG dermatitis (LAGBD) is a new en-
tity which could mimic BP and should be evaluated 
further in the future (20,21). These patients have re-
active IgA to BP antigen 2 and generalized pruritic 
bullae, but despite our hypothesis there is no signifi-
cant mucosal involvement in LAGBD patients (20-23). 
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Immunoblotting method suggests a different variety 
of targeted antigens in LAGBD (23), but unfortunately 
this technique was not available to us. With the lack 
of accurate techniques and also considerable over-
lapping features between BP, LAGBD, and linear IgA 
bullous dermatosis, clinical judgment in these cases 
might be questionable. 
Mucosal involvement is currently not a usual find-
ing in LAGBD; however, in our opinion, BP with IgA 
deposition could be reclassified as LAGBD with prom-
inent mucosal lesions.
About 25-30% of patients with mucous mem-
brane pemphigoides (MMP) may also have skin le-
sions, but mucosal involvement in MMP is usually as-
sociated with scar formation or occasionally adhesion 
bands and ectropion during disease progression. Skin 
involvement could also be associated with milia for-
mation (1). In our patients, scar formation, adhesion 
bands, or milia were not detected during 6 months 
follow-up. All patients were totally controlled with 
oral corticosteroids, so MMP could not be considered 
because systemic corticosteroids alone are usually in-
sufficient for MMP (1).
Our limitations in this retrospective study were 
small sample size, not performing mucosal biopsy 
for patients with BP, lack of a scoring system for ac-
curate evaluation of skin and mucosal involvement, 
no admission for localized BP, and no availability of 
IIF study, immunoblotting, ELISA, and IgE detecting 
techniques in our center.
In analyzing our final results using a logistic regres-
sion model, it seems that some factors other than the 
variables which were included in our study may also 
have a role in mucosal involvement in patients with 
BP. These factors include Koebner’s phenomenon 
due to denture trauma, candida infection, low oral or 
dental hygiene, micronutrient deficiencies, and the 
patient’s diet or drug consumption.
CONCLUSION
We conclude that IgA and C3 deposition at the 
dermoepidermal junction seems to be a marker of 
mucosal involvement in patients with BP. Attention 
to the direct immunofluorescence pattern in these 
patients may be helpful in treatment planning and 
prediction of mucosal involvement. 
More studies using a larger sample size, accurate 
scoring system for evaluation of skin and mucosal in-
volvement, IIF study, immunoblotting, ELISA, and IgE 
detecting techniques are recommended for more ac-
curate results. Additionally, the role of disease dura-
tion in mucosal involvement should be investigated 
in future studies.
Acknowledgment
This research project was derived from a residen-
cy thesis carried out at skin research center of Guilan 
University of Medical Sciences. We would like to ex-
press our appreciation for the cooperation of the Vice 
Chancellor of Research and Technology, Guilan Uni-
versity of Medical Sciences.
References:
1.  Bernard PH, Barradori L. Bullous pemphigoid. In: 
Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermato-
logy, 3rd ed. Philadelphia, PA: Saunders, 2012. pp. 
475-87. 
2.  Banihashemi M, Zabolinejad N, Vahabi S, Razavi 
HS. Survey of bullous pemphigoid disease in 
northern Iran. Int J Dermatol. 2015;54:1246-9. 
3.  Weedon R. The vesiculobullous reaction pattern, 
In: Weedon D, Strutton G, Rubin AI, Weedon D. 
Weedon’s skin pathology. 3rd ed, Churchill Li-
vingstone, Elsevier; 2010. pp.156-7. 
4.  Christophoridis S, Budinger L, Borradori L, Hun-
ziker T, Merk HF, Hertl M. IgG, IgA and IgE auto-
antibodies against the ectodomain of BP180 in 
patients with bullous and cicatricial pemphigoid 
and linear IgA bullous dermatosis. Br J Dermatol. 
2000;143:349-55.
5.  Kirtschig G, Wojnarowska F. IgA basement mem-
brane zone autoantibodies in bullous pemphi-
goid detect epidermal antigens of 270-280 kDa, 
230 kDa, and 180 kDa molecular weight by immu-
noblotting. Clin Exp Dermatol. 1999;24:302-7.
6.  Laskaris G, Nicolis G. Immunopathology of oral 
mucosa in bullous pemphigoid. Oral Surg Oral 
Med Oral Pathol. 1980;50:340-5.
7.  Esmaili N, Hallaji Z, Soori T, Davatchi CC. Bullous 
pemphigoid in Iranian patients: a descriptive study 
on 122 cases. Acta Medica Iranica. 2012;50:335.
8.  Schiavo AL, Ruocco E, Brancaccio G, Caccavale S, 
Ruocco V, Wolf R. Bullous pemphigoid: etiology, 
pathogenesis, and inducing factors: facts and 
controversies. Clin Dermatol. 2013;31:391-9.
9.  Bascones-Martinez A, Garcia-Garcia V, Meurman 
JH, Requena-Caballero L. Immune-mediated di-
seases: what can be found in the oral cavity? Int J 
Dermatol. 2015;54:258-70.
10. Kneisel A, Hertl M. Autoimmune bullous skin di-
seases. Part 1: Clinical manifestation. J Dtsch Der-
matol Ges. 2011;9:844-56.
11. Venning VA, Frith PA, Bron AJ, Millard PR, Wojna-
rowska F. Mucosal involvement in bullous and ci-
247ACTA DERMATOVENEROLOGICA CROATICA
Eftekhari et al. Acta Dermatovenerol Croat
IF pattern and mucosal involvement in BP patients  2018;26(3):243-248
catricial pemphigoid. A clinical and immunopat-
hological study. Br J Dermatol. 1988;118:7-15.
12. Kershenovich R, Hodak E, Mimouni D. Diagnosis 
and classification of pemphigus and bullous pem-
phigoid. Autoimmun Rev. 2014;13:477-81.
13. Maurice PD, Allen BR, Marriott DW, Powell RJ, 
Reeves WG. Skin immunofluorescence in the di-
agnosis of primary bullous diseases-a review of 
279 cases. Clin Exp Dermatol. 1986;11:352-64.
14. Cozzani E, Drosera M, Parodi A, Carrozzo M, Gan-
dolfo S, Rebora A. Frequency of IgA antibodies 
in pemphigus, bullous pemphigoid and mucous 
membrane pemphigoid. Acta Derm Venereol. 
2004;84:381-4.
15. Zone JJ, Egan CA, Taylor TB, Meyer LJ. IgA autoim-
mune disorders: development of a passive trans-
fer mouse model. J Investig Dermatol Symp Proc. 
2004;9:47-51.
16. Setterfield J, Shirlaw PJ, Kerr-Muir M, Neill S, Bho-
gal BS, Morgan P, et al. Mucous membrane pem-
phigoid: a dual circulating antibody response with 
IgG and IgA signifies a more severe and persistent 
disease. Br J Dermatol. 1998;138:602-10.
17. Zhou XP, Liu B, Xu Q, Yang Y, He CX, Zuo YG, et al. 
Serum levels of immunoglobulins G1 and G4 tar-
geting the non-collagenous 16A domain of BP180 
reflect bullous pemphigoid activity and predict 
bad prognosis. Br J Dermatol. 2016;43:141-8.
18. Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama 
Y, Hara T, et al. Correlation of IgE autoantibody to 
BP180 with a severe form of bullous pemphigoid. 
Arch Dermatol. 2008;144:41-8.
19. Valikhani M, Kavusi S, Chams-Davatchi C, Hallaji Z, 
Esmaili N, Ghandi N, et al. Impact of smoking on 
pemphigus. Int J Dermatol. 2008;47:567-70.
20. Morita K, Fujisawa A, Yagi Y, Makiura M, Fukuda 
S, Ishii N, et al. Immunoglobulin A anti-BP230 
autoantibodies in linear immunoglobulin A/im-
munoglobulin G bullous dermatosis. J Dermatol. 
2011;38:1030-2.
21. Sakaguchi M, Bito T, Oda Y, Kikusawa A, Nishigori 
C, Munetsugu T, et al. Three cases of linear IgA/IgG 
bullous dermatosis showing IgA and IgG reacti-
vity with multiple antigens, particularly laminin-
332. JAMA Dermatol. 2013;149:1308-13.
22. Li X, Tsuchisaka A, Qian H, Teye K, Ishii N, Sogame 
R, et al. Linear IgA/IgG bullous dermatosis reacts 
with multiple laminins and integrins. Eur J Der-
matol. 2015;25:418-23.
23. Shimizu S, Natsuga K, Shinkuma S, Yasui C, Tsuchi-
ya K, Shimizu H. Localized linear IgA/IgG bullous 
dermatosis. Acta Derm Venereol. 2010;90:621-4.
Eftekhari et al. Acta Dermatovenerol Croat
IF pattern and mucosal involvement in BP patients  2018;26(3):243-248
248 ACTA DERMATOVENEROLOGICA CROATICA
